UNICREDIT BANK/CALL/NOVO-NORDISK B/1150/0.1/18.09.24 | Real-time BOERSE MUENCHEN 09:45:44 2024-06-18 EDT | ||
| 0.21 EUR | -8.70% |
|
| Current month | +64.29% | ||
| 1 month | +64.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 0.21 | -8.70% |
| 24-06-17 | 0.23 | -11.54% |
| 24-06-14 | 0.26 | +13.04% |
| 24-06-13 | 0.23 | -4.17% |
| 24-06-12 | 0.24 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 18, 2024 at 09:45 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD4FHQ |
| ISIN | DE000HD4FHQ9 |
| Date issued | 2024-04-08 |
| Strike | 1,150 kr |
| Maturity | 2024-09-18 (92 Days) |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.26 € |
|---|---|
| Lowest since issue | 0.099 € |
| Spread | 0.01 € |
| Spread % | 4.76% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.5
DKK
Average target price
934.3
DKK
Spread / Average Target
-4.71%
- Stock Market
- Warrants
- Warrant
